nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—peripheral nervous system neoplasm	0.421	1	CbGaD
Dihydroergotamine—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0455	0.167	CbGbCtD
Dihydroergotamine—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0455	0.167	CbGbCtD
Dihydroergotamine—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0315	0.116	CbGbCtD
Dihydroergotamine—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0272	0.1	CbGbCtD
Dihydroergotamine—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0253	0.0931	CbGbCtD
Dihydroergotamine—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0194	0.0714	CbGbCtD
Dihydroergotamine—HTR1D—meninx—peripheral nervous system neoplasm	0.0192	0.187	CbGeAlD
Dihydroergotamine—HTR1B—dura mater—peripheral nervous system neoplasm	0.0183	0.178	CbGeAlD
Dihydroergotamine—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0181	0.0666	CbGbCtD
Dihydroergotamine—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0178	0.0654	CbGbCtD
Dihydroergotamine—HTR1D—dura mater—peripheral nervous system neoplasm	0.0177	0.172	CbGeAlD
Dihydroergotamine—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0121	0.0446	CbGbCtD
Dihydroergotamine—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0116	0.0428	CbGbCtD
Dihydroergotamine—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0107	0.0392	CbGbCtD
Dihydroergotamine—HTR1B—trigeminal nerve—peripheral nervous system neoplasm	0.00785	0.0765	CbGeAlD
Dihydroergotamine—HTR1D—trigeminal nerve—peripheral nervous system neoplasm	0.0076	0.0741	CbGeAlD
Dihydroergotamine—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00727	0.0267	CbGbCtD
Dihydroergotamine—HTR1B—cranial nerve—peripheral nervous system neoplasm	0.0056	0.0545	CbGeAlD
Dihydroergotamine—HTR1D—cranial nerve—peripheral nervous system neoplasm	0.00542	0.0528	CbGeAlD
Dihydroergotamine—HTR6—ganglion—peripheral nervous system neoplasm	0.0047	0.0458	CbGeAlD
Dihydroergotamine—HTR1B—ganglion—peripheral nervous system neoplasm	0.00283	0.0276	CbGeAlD
Dihydroergotamine—HTR1D—ganglion—peripheral nervous system neoplasm	0.00274	0.0267	CbGeAlD
Dihydroergotamine—HTR1A—ganglion—peripheral nervous system neoplasm	0.00229	0.0223	CbGeAlD
Dihydroergotamine—HTR1B—trigeminal ganglion—peripheral nervous system neoplasm	0.00139	0.0136	CbGeAlD
Dihydroergotamine—HTR1D—trigeminal ganglion—peripheral nervous system neoplasm	0.00135	0.0131	CbGeAlD
Dihydroergotamine—HTR1B—brainstem—peripheral nervous system neoplasm	0.00123	0.012	CbGeAlD
Dihydroergotamine—HTR1D—brainstem—peripheral nervous system neoplasm	0.00119	0.0116	CbGeAlD
Dihydroergotamine—HTR1A—brainstem—peripheral nervous system neoplasm	0.000994	0.00968	CbGeAlD
Dihydroergotamine—ADRA2A—trigeminal ganglion—peripheral nervous system neoplasm	0.000787	0.00767	CbGeAlD
Dihydroergotamine—HTR1A—cerebellum—peripheral nervous system neoplasm	0.00049	0.00477	CbGeAlD
Dihydroergotamine—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000438	0.00427	CbGeAlD
Dihydroergotamine—Ergotamine—ABCB1—peripheral nervous system neoplasm	0.000412	0.509	CrCbGaD
Dihydroergotamine—Bromocriptine—ABCB1—peripheral nervous system neoplasm	0.000398	0.491	CrCbGaD
Dihydroergotamine—ADRA2A—cerebellum—peripheral nervous system neoplasm	0.000343	0.00335	CbGeAlD
Dihydroergotamine—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000244	0.0012	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Etoposide—peripheral nervous system neoplasm	0.000244	0.0012	CcSEcCtD
Dihydroergotamine—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.000243	0.00119	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000242	0.00119	CcSEcCtD
Dihydroergotamine—Hot flush—Doxorubicin—peripheral nervous system neoplasm	0.000242	0.00119	CcSEcCtD
Dihydroergotamine—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000242	0.00119	CcSEcCtD
Dihydroergotamine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000241	0.00119	CcSEcCtD
Dihydroergotamine—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000241	0.00118	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000241	0.00118	CcSEcCtD
Dihydroergotamine—Migraine—Epirubicin—peripheral nervous system neoplasm	0.000241	0.00118	CcSEcCtD
Dihydroergotamine—Menopausal symptoms—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.00118	CcSEcCtD
Dihydroergotamine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00024	0.00118	CcSEcCtD
Dihydroergotamine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00024	0.00118	CcSEcCtD
Dihydroergotamine—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000239	0.00118	CcSEcCtD
Dihydroergotamine—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000239	0.00117	CcSEcCtD
Dihydroergotamine—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.000238	0.00117	CcSEcCtD
Dihydroergotamine—Malaise—Etoposide—peripheral nervous system neoplasm	0.000237	0.00116	CcSEcCtD
Dihydroergotamine—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000237	0.00116	CcSEcCtD
Dihydroergotamine—Face oedema—Epirubicin—peripheral nervous system neoplasm	0.000236	0.00116	CcSEcCtD
Dihydroergotamine—Vertigo—Etoposide—peripheral nervous system neoplasm	0.000236	0.00116	CcSEcCtD
Dihydroergotamine—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000235	0.00115	CcSEcCtD
Dihydroergotamine—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000234	0.00115	CcSEcCtD
Dihydroergotamine—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000234	0.00115	CcSEcCtD
Dihydroergotamine—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000234	0.00115	CcSEcCtD
Dihydroergotamine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000232	0.00114	CcSEcCtD
Dihydroergotamine—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.000231	0.00113	CcSEcCtD
Dihydroergotamine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00023	0.00113	CcSEcCtD
Dihydroergotamine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00023	0.00113	CcSEcCtD
Dihydroergotamine—Rash—Topotecan—peripheral nervous system neoplasm	0.00023	0.00113	CcSEcCtD
Dihydroergotamine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.00023	0.00113	CcSEcCtD
Dihydroergotamine—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.00023	0.00113	CcSEcCtD
Dihydroergotamine—Headache—Topotecan—peripheral nervous system neoplasm	0.000229	0.00112	CcSEcCtD
Dihydroergotamine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000228	0.00112	CcSEcCtD
Dihydroergotamine—Rash—Tretinoin—peripheral nervous system neoplasm	0.000228	0.00112	CcSEcCtD
Dihydroergotamine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000228	0.00112	CcSEcCtD
Dihydroergotamine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000228	0.00112	CcSEcCtD
Dihydroergotamine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000228	0.00112	CcSEcCtD
Dihydroergotamine—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000228	0.00112	CcSEcCtD
Dihydroergotamine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000227	0.00112	CcSEcCtD
Dihydroergotamine—Headache—Tretinoin—peripheral nervous system neoplasm	0.000227	0.00111	CcSEcCtD
Dihydroergotamine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000227	0.00111	CcSEcCtD
Dihydroergotamine—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000227	0.00111	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000226	0.00111	CcSEcCtD
Dihydroergotamine—Pain—Vincristine—peripheral nervous system neoplasm	0.000226	0.00111	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000226	0.00111	CcSEcCtD
Dihydroergotamine—Rash—Melphalan—peripheral nervous system neoplasm	0.000225	0.00111	CcSEcCtD
Dihydroergotamine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000225	0.00111	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000224	0.0011	CcSEcCtD
Dihydroergotamine—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000223	0.0011	CcSEcCtD
Dihydroergotamine—Migraine—Doxorubicin—peripheral nervous system neoplasm	0.000223	0.00109	CcSEcCtD
Dihydroergotamine—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000221	0.00108	CcSEcCtD
Dihydroergotamine—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000219	0.00107	CcSEcCtD
Dihydroergotamine—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.000218	0.00107	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000218	0.00107	CcSEcCtD
Dihydroergotamine—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000218	0.00107	CcSEcCtD
Dihydroergotamine—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000217	0.00107	CcSEcCtD
Dihydroergotamine—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000217	0.00107	CcSEcCtD
Dihydroergotamine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000217	0.00107	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000216	0.00106	CcSEcCtD
Dihydroergotamine—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000216	0.00106	CcSEcCtD
Dihydroergotamine—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.000216	0.00106	CcSEcCtD
Dihydroergotamine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000215	0.00106	CcSEcCtD
Dihydroergotamine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000215	0.00106	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000213	0.00105	CcSEcCtD
Dihydroergotamine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000212	0.00104	CcSEcCtD
Dihydroergotamine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000212	0.00104	CcSEcCtD
Dihydroergotamine—Dysphagia—Epirubicin—peripheral nervous system neoplasm	0.000211	0.00104	CcSEcCtD
Dihydroergotamine—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.00021	0.00103	CcSEcCtD
Dihydroergotamine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000209	0.00103	CcSEcCtD
Dihydroergotamine—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000209	0.00103	CcSEcCtD
Dihydroergotamine—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000209	0.00103	CcSEcCtD
Dihydroergotamine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000209	0.00102	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000207	0.00102	CcSEcCtD
Dihydroergotamine—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000206	0.00101	CcSEcCtD
Dihydroergotamine—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000204	0.001	CcSEcCtD
Dihydroergotamine—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000203	0.000999	CcSEcCtD
Dihydroergotamine—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000203	0.000998	CcSEcCtD
Dihydroergotamine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000203	0.000995	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000202	0.000993	CcSEcCtD
Dihydroergotamine—Hypotension—Etoposide—peripheral nervous system neoplasm	0.0002	0.000983	CcSEcCtD
Dihydroergotamine—Pain—Cisplatin—peripheral nervous system neoplasm	0.0002	0.000982	CcSEcCtD
Dihydroergotamine—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.00098	CcSEcCtD
Dihydroergotamine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000197	0.000967	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000196	0.000964	CcSEcCtD
Dihydroergotamine—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000195	0.00096	CcSEcCtD
Dihydroergotamine—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000195	0.000958	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000195	0.000957	CcSEcCtD
Dihydroergotamine—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000194	0.000954	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000193	0.000947	CcSEcCtD
Dihydroergotamine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000192	0.000945	CcSEcCtD
Dihydroergotamine—ABCB1—cerebellum—peripheral nervous system neoplasm	0.000191	0.00186	CbGeAlD
Dihydroergotamine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000191	0.000938	CcSEcCtD
Dihydroergotamine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.00019	0.000936	CcSEcCtD
Dihydroergotamine—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000935	CcSEcCtD
Dihydroergotamine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.00019	0.000932	CcSEcCtD
Dihydroergotamine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000188	0.000925	CcSEcCtD
Dihydroergotamine—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000188	0.000923	CcSEcCtD
Dihydroergotamine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000188	0.000923	CcSEcCtD
Dihydroergotamine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000187	0.000917	CcSEcCtD
Dihydroergotamine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000186	0.000915	CcSEcCtD
Dihydroergotamine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000185	0.000908	CcSEcCtD
Dihydroergotamine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000185	0.000907	CcSEcCtD
Dihydroergotamine—Pain—Etoposide—peripheral nervous system neoplasm	0.000183	0.0009	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000183	0.000899	CcSEcCtD
Dihydroergotamine—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000892	CcSEcCtD
Dihydroergotamine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000182	0.000892	CcSEcCtD
Dihydroergotamine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000181	0.000889	CcSEcCtD
Dihydroergotamine—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000887	CcSEcCtD
Dihydroergotamine—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000872	CcSEcCtD
Dihydroergotamine—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000868	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000177	0.000867	CcSEcCtD
Dihydroergotamine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000176	0.000864	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000175	0.000861	CcSEcCtD
Dihydroergotamine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000175	0.000859	CcSEcCtD
Dihydroergotamine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000175	0.000857	CcSEcCtD
Dihydroergotamine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000173	0.00085	CcSEcCtD
Dihydroergotamine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000173	0.000849	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000172	0.000846	CcSEcCtD
Dihydroergotamine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000172	0.000845	CcSEcCtD
Dihydroergotamine—Urticaria—Etoposide—peripheral nervous system neoplasm	0.00017	0.000836	CcSEcCtD
Dihydroergotamine—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000832	CcSEcCtD
Dihydroergotamine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000169	0.000832	CcSEcCtD
Dihydroergotamine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000169	0.000832	CcSEcCtD
Dihydroergotamine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000169	0.000832	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000168	0.000826	CcSEcCtD
Dihydroergotamine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000168	0.000826	CcSEcCtD
Dihydroergotamine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000168	0.000824	CcSEcCtD
Dihydroergotamine—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000168	0.000824	CcSEcCtD
Dihydroergotamine—Rash—Vincristine—peripheral nervous system neoplasm	0.000167	0.000819	CcSEcCtD
Dihydroergotamine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000167	0.000818	CcSEcCtD
Dihydroergotamine—Headache—Vincristine—peripheral nervous system neoplasm	0.000166	0.000814	CcSEcCtD
Dihydroergotamine—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000807	CcSEcCtD
Dihydroergotamine—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000803	CcSEcCtD
Dihydroergotamine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000163	0.000801	CcSEcCtD
Dihydroergotamine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000163	0.0008	CcSEcCtD
Dihydroergotamine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00016	0.000786	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000158	0.000775	CcSEcCtD
Dihydroergotamine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000774	CcSEcCtD
Dihydroergotamine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000157	0.000772	CcSEcCtD
Dihydroergotamine—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000771	CcSEcCtD
Dihydroergotamine—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.00077	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000764	CcSEcCtD
Dihydroergotamine—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000763	CcSEcCtD
Dihydroergotamine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000154	0.000755	CcSEcCtD
Dihydroergotamine—Chills—Epirubicin—peripheral nervous system neoplasm	0.000152	0.000745	CcSEcCtD
Dihydroergotamine—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000152	0.000745	CcSEcCtD
Dihydroergotamine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.00074	CcSEcCtD
Dihydroergotamine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000149	0.00073	CcSEcCtD
Dihydroergotamine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000147	0.000724	CcSEcCtD
Dihydroergotamine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000147	0.000724	CcSEcCtD
Dihydroergotamine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000147	0.00072	CcSEcCtD
Dihydroergotamine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000716	CcSEcCtD
Dihydroergotamine—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000713	CcSEcCtD
Dihydroergotamine—Tension—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000709	CcSEcCtD
Dihydroergotamine—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000702	CcSEcCtD
Dihydroergotamine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000142	0.000696	CcSEcCtD
Dihydroergotamine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000695	CcSEcCtD
Dihydroergotamine—Chills—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000689	CcSEcCtD
Dihydroergotamine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000139	0.000682	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000671	CcSEcCtD
Dihydroergotamine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000136	0.000669	CcSEcCtD
Dihydroergotamine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000664	CcSEcCtD
Dihydroergotamine—Rash—Etoposide—peripheral nervous system neoplasm	0.000135	0.000664	CcSEcCtD
Dihydroergotamine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000135	0.000663	CcSEcCtD
Dihydroergotamine—Headache—Etoposide—peripheral nervous system neoplasm	0.000134	0.000659	CcSEcCtD
Dihydroergotamine—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000656	CcSEcCtD
Dihydroergotamine—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000652	CcSEcCtD
Dihydroergotamine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.00065	CcSEcCtD
Dihydroergotamine—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000649	CcSEcCtD
Dihydroergotamine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000643	CcSEcCtD
Dihydroergotamine—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000639	CcSEcCtD
Dihydroergotamine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000127	0.000625	CcSEcCtD
Dihydroergotamine—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000624	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000621	CcSEcCtD
Dihydroergotamine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000615	CcSEcCtD
Dihydroergotamine—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000615	CcSEcCtD
Dihydroergotamine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000615	CcSEcCtD
Dihydroergotamine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000613	CcSEcCtD
Dihydroergotamine—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000124	0.000608	CcSEcCtD
Dihydroergotamine—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000603	CcSEcCtD
Dihydroergotamine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000602	CcSEcCtD
Dihydroergotamine—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000601	CcSEcCtD
Dihydroergotamine—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000595	CcSEcCtD
Dihydroergotamine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000591	CcSEcCtD
Dihydroergotamine—Oedema—Epirubicin—peripheral nervous system neoplasm	0.00012	0.00059	CcSEcCtD
Dihydroergotamine—Shock—Epirubicin—peripheral nervous system neoplasm	0.000118	0.00058	CcSEcCtD
Dihydroergotamine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000577	CcSEcCtD
Dihydroergotamine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000576	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000116	0.00057	CcSEcCtD
Dihydroergotamine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000569	CcSEcCtD
Dihydroergotamine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000569	CcSEcCtD
Dihydroergotamine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000567	CcSEcCtD
Dihydroergotamine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.000563	CcSEcCtD
Dihydroergotamine—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000562	CcSEcCtD
Dihydroergotamine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000557	CcSEcCtD
Dihydroergotamine—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000551	CcSEcCtD
Dihydroergotamine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.00055	CcSEcCtD
Dihydroergotamine—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000546	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000537	CcSEcCtD
Dihydroergotamine—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000537	CcSEcCtD
Dihydroergotamine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000534	CcSEcCtD
Dihydroergotamine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000533	CcSEcCtD
Dihydroergotamine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000108	0.00053	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000528	CcSEcCtD
Dihydroergotamine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000526	CcSEcCtD
Dihydroergotamine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000524	CcSEcCtD
Dihydroergotamine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.00052	CcSEcCtD
Dihydroergotamine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000519	CcSEcCtD
Dihydroergotamine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000513	CcSEcCtD
Dihydroergotamine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.00051	CcSEcCtD
Dihydroergotamine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000509	CcSEcCtD
Dihydroergotamine—Pain—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000504	CcSEcCtD
Dihydroergotamine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000497	CcSEcCtD
Dihydroergotamine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000494	CcSEcCtD
Dihydroergotamine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	9.98e-05	0.00049	CcSEcCtD
Dihydroergotamine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	9.91e-05	0.000487	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	9.9e-05	0.000486	CcSEcCtD
Dihydroergotamine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	9.88e-05	0.000485	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	9.82e-05	0.000482	CcSEcCtD
Dihydroergotamine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	9.78e-05	0.000481	CcSEcCtD
Dihydroergotamine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	9.66e-05	0.000475	CcSEcCtD
Dihydroergotamine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	9.58e-05	0.000471	CcSEcCtD
Dihydroergotamine—Urticaria—Epirubicin—peripheral nervous system neoplasm	9.54e-05	0.000469	CcSEcCtD
Dihydroergotamine—Pain—Doxorubicin—peripheral nervous system neoplasm	9.5e-05	0.000467	CcSEcCtD
Dihydroergotamine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	9.5e-05	0.000466	CcSEcCtD
Dihydroergotamine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	9.5e-05	0.000466	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	9.16e-05	0.00045	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	9.09e-05	0.000446	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	8.85e-05	0.000435	CcSEcCtD
Dihydroergotamine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	8.83e-05	0.000434	CcSEcCtD
Dihydroergotamine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	8.79e-05	0.000432	CcSEcCtD
Dihydroergotamine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	8.79e-05	0.000432	CcSEcCtD
Dihydroergotamine—Asthenia—Epirubicin—peripheral nervous system neoplasm	8.62e-05	0.000423	CcSEcCtD
Dihydroergotamine—Pruritus—Epirubicin—peripheral nervous system neoplasm	8.5e-05	0.000417	CcSEcCtD
Dihydroergotamine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	8.22e-05	0.000404	CcSEcCtD
Dihydroergotamine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	8.19e-05	0.000402	CcSEcCtD
Dihydroergotamine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	7.97e-05	0.000392	CcSEcCtD
Dihydroergotamine—Dizziness—Epirubicin—peripheral nervous system neoplasm	7.94e-05	0.00039	CcSEcCtD
Dihydroergotamine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	7.86e-05	0.000386	CcSEcCtD
Dihydroergotamine—Vomiting—Epirubicin—peripheral nervous system neoplasm	7.64e-05	0.000375	CcSEcCtD
Dihydroergotamine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	7.6e-05	0.000373	CcSEcCtD
Dihydroergotamine—Rash—Epirubicin—peripheral nervous system neoplasm	7.57e-05	0.000372	CcSEcCtD
Dihydroergotamine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	7.57e-05	0.000372	CcSEcCtD
Dihydroergotamine—Headache—Epirubicin—peripheral nervous system neoplasm	7.52e-05	0.00037	CcSEcCtD
Dihydroergotamine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	7.35e-05	0.000361	CcSEcCtD
Dihydroergotamine—Nausea—Epirubicin—peripheral nervous system neoplasm	7.13e-05	0.00035	CcSEcCtD
Dihydroergotamine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	7.07e-05	0.000347	CcSEcCtD
Dihydroergotamine—Rash—Doxorubicin—peripheral nervous system neoplasm	7.01e-05	0.000344	CcSEcCtD
Dihydroergotamine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	7e-05	0.000344	CcSEcCtD
Dihydroergotamine—Headache—Doxorubicin—peripheral nervous system neoplasm	6.96e-05	0.000342	CcSEcCtD
Dihydroergotamine—Nausea—Doxorubicin—peripheral nervous system neoplasm	6.6e-05	0.000324	CcSEcCtD
